Longeviti is a technology company.
Longeviti develops innovative platforms for complex brain surgeries, including implantable devices that enhance patient imaging and reduce radiation exposure.
Longeviti has raised $10.0M across 1 funding round.
Longeviti has raised $10.0M in total across 1 funding round.
Longeviti has raised $10.0M in total across 1 funding round.
Longeviti's investors include Agent Capital, Bain Capital Life Sciences, Cofounders Capital.
Longeviti Neuro Solutions is a Baltimore-based neurotechnology company developing innovative, low-profile intracranial implants for complex brain surgeries. It builds the patented L.I.D. (Low-profile Intracranial Devices) platform, including FDA-cleared products like ClearFit® (for cranial reconstruction enabling post-surgical ultrasound imaging) and InvisiShunt®/InvisiLead (for shunt and lead accommodation while restoring skull contour).[1][2][3][4] These serve neurosurgeons and patients with neurological disorders, solving high complication rates (40-60%) from non-anatomic hardware placement by combining functional neurosurgery, neuro-reconstruction, and neuro-plastic solutions to improve outcomes, reduce procedures, and minimize visible deformities.[2][3]
Launched in 2015 with laser technology from Johns Hopkins and early TEDCO support, Longeviti has commercialized multiple implants since 2018, raised initial $2M equity, and in 2025 is pursuing up to $12.6M in growth capital to scale, positioning it as a university tech success story with potential for broader neurotechnology impact.[2][3]
Longeviti Neuro Solutions was founded in 2015 by a team of industry-leading medical device executives, neurosurgeons, and biomedical engineers, including co-founder and CEO Jesse Christopher, a veteran from Fortune 500 medtech firm Stryker Corp.[1][2][3] The idea emerged from Johns Hopkins laser technology, addressing unmet needs in complex brain surgeries where patients face multiple procedures, long recoveries, and complications from bulky implants that ignore anatomical fit—termed "implant accommodation" by Christopher.[1][2]
Early traction came via TEDCO’s Maryland Innovation Initiative, enabling $2M equity raise in year one and Q3 2018 launches of ClearFit (for bony defects with imaging) and InvisiShunt (first-in-human publication highlighting complication reductions).[2][3][4] This marked Longeviti as a local success, evolving from lab therapies to a comprehensive neurotechnology portfolio merging robotics, navigation, brain interfaces, and reconstruction.[1][3]
Longeviti rides the neurotechnology boom, blending AI-driven navigation, wireless interfaces, and minimally invasive implants amid rising demand for brain surgery solutions in neurological disorders like hydrocephalus or tumors.[1][3] Timing aligns with post-2020 medtech innovation surge, where complication reductions and imaging tech address healthcare pressures for better outcomes and fewer revisions.[2][4]
Market forces favor it: aging populations increase brain surgery needs, while university spinouts like Longeviti (Johns Hopkins roots) benefit from ecosystems like TEDCO; its portfolio influences standards by pioneering combined functional/reconstructive devices, potentially enabling future brain-machine interfaces.[1][2][3] As a private player in a dynamic sector, it exemplifies startup disruption against legacy hardware limitations.[5]
Longeviti's $12.6M raise signals acceleration toward a "comprehensive neurotechnology portfolio," expanding ClearFit/Invisi products and pipeline amid 2025 medtech funding resilience.[1][2] Trends like AI-ultrasound integration and neuro-plastics will shape it, with influence growing via publications, partnerships, and potential acquisitions (e.g., Harpoon Medical parallels).[2][3]
Expect scaled commercialization, international trials, and ecosystem leadership in anatomical neuro-implants—transforming complex surgeries from high-risk to routine, as its L.I.D. platform redefines patient normalcy.[3][4]
Longeviti has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Venture Round in August 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2025 | $10.0M Venture Round | Agent Capital, Bain Capital Life Sciences, Cofounders Capital |